Participants will form small “biotech taskforce” teams. Each team’s mission is to design and pitch a future-forward microbiome therapeutic concept addressing a high priority unmet need in GI or infectious diseases

• Target Prioritization: What indication or patient population should be the next focus for microbiome therapeutics, and why?
• Modality & Mechanism: Should your therapy use co-cultured consortia, synbiotics, engineered strains, or another platform? What’s the core mechanism of action?
• Regulatory & Clinical Strategy: What endpoints and biomarkers will be key to regulatory success, and how do you de-risk development early on?
• Commercial Viability: What’s your plan for manufacturing, delivery (oral, capsule, etc.), and payer buy-in to make this therapy viable in real-world healthcare systems?